exploration in Medical Technology

Impact Medical Solutions Announces Appointment of New Director and Corporate Update

... services to small-cap companies. He is also the President and CEO of Orex exploration Inc., a junior gold exploration company, and CEO of Argex Silver Capital Inc., a Capital Pool Company. ....

West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial

... The West Wireless Health Institute ( www.westwirelesshealth.org ) is one of the first medical research organizations in the world supporting the exploration and application of wireless technologies to advance human health and well-being. Along with Scripps Health and Qualcomm, the Institute is fostering ...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

... even then, 40 to 60 percent of patients experience recurring carcinoma tumors. The survival rate for advanced HNSCC is less than 40 percent. The exploration of low-dose, long-term oral chemotherapy agents in adjuvant (i.e. follow-up) cancer treatment represents new and exciting territory for Karmanos ...

BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available

... on federal funding of human embryonic stem cell research," notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. "However, the exploration of induced pluripotent stem cells and the pursuit of cell-based therapies and drug discovery and development research using adult human stem cells ...

NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds

... at NovaBay. "We see this collaboration as adding significant depth to our preclinical and clinical development programs and to the continued exploration of the properties of our Aganocide compounds. We expect that our joint efforts will provide important information that may further accelerate our ...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... that is better tolerated, shorter in duration and delivers higher sustained viral response rates. We are pleased to participate in the first clinical exploration of an all-oral, direct antiviral regimen towards that goal." "The combination of oral antiviral therapies for HCV represents an exciting step in ...

Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing

... from the peer-reviewed literature, as well as anecdotal reports Healthpoint has received from clinicians, we determined that formal scientific exploration was an appropriate course of action to more fully characterize the therapeutic properties of collagenase," commented Bert Slade, MD, FAAAAI, Chief ...

Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting

... used for palliative treatment in patients with metastatic castration resistant prostate cancer and bone metastases, and these data encourage further exploration of the ability of tumor antigen release by radiotherapy to serve as an immune-supportive intervention in combination with ipilimumab as a potentially ...

Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

... - Results from Gene Identification Studies Presented at ASCO Support Further exploration of Possible Tests to Predict Response to Targeted Therapies for Colon and Breast Cancers - REDWOOD CITY, Calif., May 31 ...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

... non-Hodgkin's lymphoma cases. "These findings reinforce the clinical potential of mTOR inhibition with TORISEL. Wyeth is committed to the continued exploration of mTOR inhibition with TORISEL for the treatment of a variety of cancers," says Joseph S. Camardo, M.D., Senior Vice President, Global Medical ...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

... with additional information about the efficacy and safety of TORISEL for the treatment of advanced RCC patients. Wyeth is committed to the continued exploration of mTOR inhibition with TORISEL for the treatment of a variety of cancers," says Joseph S. Camardo, M.D., Senior Vice President, Global ...

Basic Science Discoveries Yield Progress in Hepatology

... application of systems biology -- which focuses on interactions in biological systems -- to clinical problems in hepatology. As such, the systematic exploration of RNA, protein and metabolic profiles in hepatitis, fatty liver and cancer may help to identify patients at particular risk for developing severe ...

St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia

... of 18 patients. They found that the gene expression profiles for the top 50 genes also predicted methotrexate response in those patients. Further exploration of the genes identified in this study could yield clinical benefits. "Some of these could become potential targets for developing other drugs that ...

ImaRx Therapeutics Transitions Business Strategy

... of a financing event prior to that date. In order to preserve its existing cash resources and minimize financing risk, the Company has commenced exploration of strategic alternatives whereby part or all of the ongoing expenses for its SonoLysis development program may be borne by a third party. Greg ...

New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer

... future events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies that extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers ...

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

... further demonstrates perifosine's promising activity as a single agent. The combination of perifosine with sorafenib is of great interest and further exploration with this combination in patients who fail a prior TKI is warranted," stated Dr. Robert Figlin, who continued, "We are anxious to further explore ...

Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development

... represent a new class of drugs with in vitro activity against chronic myelogenous leukemia (CML) variants with BCR-ABL mutations, warranting their exploration as potential new treatments for patients with imatinib-resistant forms of cancer. Preliminary in vitro data suggest these compounds are selective for ...

Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study

... as soon as possible and intend to meet with regulatory agencies to discuss next steps for regulatory approval. We also plan to continue our current exploration of GATTEX in other indications with high unmet needs, including chemotherapy-induced GI mucositis and necrotizing enterocolitis." There are several ...

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer

... information, future events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...

Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals

... during HIV replication. But until recently, several barriers, including the stability of the RNA-RNA binding during experimentation, had prevented exploration of tRNA as a drug target. Working in collaboration with Southern Research, Trana Discovery refined their technology to overcome those barriers in ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... future events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

... whether as a result of new information, future events or otherwise. Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

... events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

... Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007. "The results of this study indicated that further exploration of this combination is warranted, as the established effect of COPAXONE(r) on disease activity may be boosted when used in combination with ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

... Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007. "The results of this study indicated that further exploration of this combination is warranted, as the established effect of COPAXONE(R) on disease activity may be boosted when used in combination with ...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

... Melanoma," at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO). "Hsp90 inhibition is of significant interest for exploration as an antitumor approach in melanoma, as members of the BRAF signaling pathway are client proteins and are implicated in the majority of melanomas," ...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

... from its investor relations department. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

... events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, ...